New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 8, 2014
13:48 EDTZGNXZogenix drops 10% after competitor gets Priority Review
Shares of Zogenix (ZGNX) are moving lower after Purdue Pharma announced earlier today that the FDA has granted Priority Review designation for its once-daily, single-entity hydrocodone bitartrate tablet. The investigational pain medication was formulated to incorporate abuse-deterrent properties designed to make the product more difficult to manipulate for the purpose of misuse or abuse, Purdue stated. Shares of Zogenix, which has a competing pain killer drug called Zohydro ER without abuse-deterrent properties, are down 10%, or 22c, to $1.91 in afternoon trading.
News For ZGNX From The Last 14 Days
Check below for free stories on ZGNX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2014
08:56 EDTZGNXOn The Fly: Pre-market Movers
Subscribe for More Information
07:31 EDTZGNXZogenix Zohydro ER demonstrates sustained 12-hour pain relief
Zogenix announced new post-hoc analysis data showing that the indicated 12-hour dose of Zohydro ER, Extended-Release Capsules, CII, provided durable pain relief over the entire dosing interval. This finding is important because a major concern for all extended-release pain medications is the potential for lack of consistent pain relief throughout the entire day, especially at the end of the dosing.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use